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Histologic and clinical characteristics associated with rapidly progressive invasive cervical
cancer are presented in this preliminary report from a population-based study involving all
patients in Connecticut diagnosed with cervical cancer from March 1, 1985. Rapidly progressive
invasive cervical cancer, i.e., invasive cancer diagnosed within three years of a true negative Pap
smear, is more likely to occur in younger women with high annual incomes (61 percent >
$40,000) who report a greater frequency ofbenign gynecologic conditions (uterine leiomyomata,
vaginitis) compared to a control cervical cancer group. These preliminary data suggest that as
many as 35 percent of the rapidly progressive cervical cancers are likely to be adenocarcinomas.
Because they are mostly endocervical in origin, they may not be detected cytologically ifscrapers
or cotton swabs are used to sample the endocervical canal. New cytologic screening techniques
using brushes may identify these lesions earlier and should routinely be employed in cytologic
screening for cervical neoplasia. The difficulty in early detection of this form of the disease
requires that physicians rapidlyassess patients with unexplained pelvic and lower abdominal pain,
vaginal discharge, or abnormal vaginal bleeding since early recognition is the only chance for
cure. Further analyses ofthis population ofwomen will be made to identify additional risk factors
when the study data are complete.
INTRODUCTION
Cervical cancer is the only cancer for which there has been long-term and
widespread screening. The Papanicolaou (Pap) test, a cytologic method used to detect
precursor lesions of the cervix, has contributed to the decreasing incidence and
mortality rates. While it has been assumed that the natural history of cervical cancer
has a long pre-clinical phase, data have begun to accumulate which suggest that a
significant portion of invasive cervical cancer cases progress rapidly and, therefore,
cannot be prevented with the existing early detection programs [1-3]. More recent
data indicate that the percentage ofsuch rapidly developing cases may be as high as 25
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percent to 33 percent [4-7]. The interval from the last negativecytological finding to a
diagnosis ofinvasive cancer varied between two and five years in the latter studies. So
far, no distinctive characteristics have been reported to single out these women, except
in a Yale University report on clinical management of rapidly progressive invasive
cervical cancer patients, where 88 percent were found to be less than 40 years old [8].
A major weakness in these studies is the lackofverification ofthe "negative smear" by
a second cytopathologist, which leads to the inclusion offalse-negative cases with the
rapidly progressive invasive cervical cancer group.
The purpose of this paper is to present preliminary data from a population-based
study where Pap smear data has been verified by experienced cytopathologists in order
to present histologic findings and clinical symptomatology associated with rapidly
progressive cervical cancer. It is based on data collected for a cancer control project
aiming to improve early detection methods for cervical cancer through interventions
developed from the study results [9]. It is hoped that this preliminary report will serve
as partofa statewide cervical cancer intervention sincethereport is alerting physicians
to the difficulties ofdetecting the pre-invasive stage ofadenocarcinoma using the Pap
test.
MATERIALS AND METHODS
This investigation is being conducted by the Cancer Control Research Unit of
the Department of Epidemiology and Public Health at Yale University School of
Medicine. The current project is enrolling all incident cases ofinvasive cervical cancer
diagnosed in Connecticut between March 1, 1985, and March 1, 1990. Information on
eligible patients is collected with a pre-tested, structured questionnaire administered
by a telephone interview. The study to date has completed 373 interviews, and
cytologic review has been completed for 223 patients.
Cytology slides are collected and reviewed for all invasive cancer cases. Based on
information obtainedduringtheinterview, all physicians whomay haveperformed Pap
tests on the patient in the past are contacted. Subsequently, cytology slides are
requested from the various laboratories and reviewed by the pathologists. The medical
review committee studies all reports from cervical biopsies and/or hysterectomies and
all reports from available Pap tests. Each case is then classified by the medical review
committee [consisting of a gynecologic oncologist (PES), a cytopathologist (DML),
and an epidemiologist (JWM)] into one of four categories that identify the reason for
failure. These categories are: (1) not reached by screening, (2) misread Pap smears, (3)
detected by screening test but not adequately treated, and (4) rapidly progressive
disease not detected through routine screening procedures.
Rapidly progressive invasive cervical cancer is defined as cervical cancer occurring
within three years of the last true negative Pap smear. The three-year interval was
selected based on the American Cancer Society's recommendation for triennial Pap
smear screening. Discrepancies between original Pap smear readings and those of the
review cytopathologists are resolved by having an additional expert cytopathologist
(MM) review the slides. Thirty-one cases have been classified as rapidly progressive to
date. Patients in the first three categories of the classification scheme have been
grouped together and form the cervical cancer comparison group, i.e., patients with
"slowly developing" cervical cancers. This comparison group includes 166 cases. It
should be pointed out that the comparison group may include some women who would
be classified as rapidly progressive had they been screened with a Pap smear; this
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TABLE 1
Distribution of Age and Income Among Patients with Rapidly Progressive Invasive Cervical Cancer
and Two Comparison Groups
Rapidly Progressive Invasive In Situ
Cervical Cancer Cervical Cancer Cervical Cancer
Factors n 31 n =166 n = 76
Age at Diagnosis
<35 years 29 27 23
35-44 33 21 23
45-54 32 18 24
55-64 3 18 18
65+ years 3 16 12
Income
Less than $40,000 29 73 68
$40,000ormore 61 18 24
Refused information 10 9 8
possibility may lead to a more conservative interpretation ofthe results. An additional
76 patients with carcinoma in situ (CIS) ofthe cervix have been included as a second
comparison group. These were group-matched for age within a five-year interval with
the 1985 and 1986 cases.
International Federation ofGynecologists and Obstetricians (F.I.G.O.) staging was
available for 25 of 31 patients with rapidly progressive invasive cervical cancer.
Twenty-four were F.I.G.O. stage IB and one stage IAii. Thus, all ofthe cancers staged
were clinically confined to the cervix. F.I.G.O. staging for the control group ofcervical
cancers is not presently available. Among the rapidly progressive cases, the interval
from the last normal Pap smear to the time ofdiagnosis was six months or less in five
patients, 7 to 12 months in ten, 13 to 18 months in ten, 19 to 24 months in two, 25 to 30
months in three patients, and 31 to 36 months in one patient.
Since the comparison groups in thiscase-control analysis may be subject to the same
risk factors as the cases, these risk factors are evaluated with respect to their "relative
influence" on a woman developing rapidly progressive invasive cervical cancer.
Because the data presented here are preliminary, analysis was restricted to contin-
gency tables, and statistical significance is not being reported.
RESULTS
Preliminary analysis ofsome risk factors associated with cervical cancer reveals that
rapidly progressive invasive cervical cancer occurs most often in a younger population,
since 93 percent was diagnosed in women under age 54 versus 66 percent ofthe control
groupofinvasive cancer patients and 70 percent ofthe CIS group (Table 1). Sixty-one
percent ofwomen with the rapidly progressive invasive cervical cancer have an annual
family income of $40,000 versus 18 percent and 23 percent, respectively, for the two
control groups.
Patients in the rapidly progressive cervical cancer group are more likely to report
ever having had gynecologic disorders, specifically uterine leiomyomata and vaginitis,
than the two comparison groups (Table 2). The rest ofthe conditions are reported by
very few patients in all ofthe groups.
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TABLE 2
Distribution of Previous Gynecologic Disorders and Symptoms Associated with Cervical Cancer
Among Rapidly Progressive Cases and Two Comparison Groups
Rapidly Progressive Invasive In Situ
Cervical Cancer Cervical Cancer Cervical Cancer
n= 31 n 166 n=76
Previous Gynecologic Disorders
Vaginitis 58 36 46
Uterine leiomyoma 23 7 9
Endometriosis 6 1 12
Pelvic inflammatory disease 3 5 3
Ovarian cysts 3 8 9
Genital warts 3 2 8
Sexually transmitted disease 3 4 8
Herpes 1 5
Symptoms Associated with Cervical Cancer
Vaginal bleeding 57 64 20
Spotting after intercourse 23 24 13
Abdominal pain 26 42 26
Vaginal discharge 26 40 25
Weight loss 6 16 4
Difficulty urinating 3 12 8
Among the symptoms most frequently associated with cervical cancer, abnormal
vaginal bleeding is equally reported by the rapidly progressive cases (57 percent) and
the control invasive cancer group (64 percent). Pelvic or lower abdominal pain and
vaginal discharge is reported less frequently by the patients with rapidly progressive
cancer. Additional symptoms of weight loss and difficulty urinating are not common
among the cases. As expected, patients with CIS are reporting a substantially lower
frequency ofsymptoms than either ofthe invasive cancer groups.
Substantial differences in histology (Table 3) are being observed between the
two groups of invasive cancer patients. Thirty-five percent of women with rapidly
progressive cervical cancer are diagnosed with adenocarcinoma, whereas only 11
percent of the invasive comparison group has adenocarcinoma. An additional 10
percent ofthe rapidly progressive cases have adenosquamous carcinoma versus only 3
percent among the invasive comparison group.
DISCUSSION
The identification of risk factors and characteristics associated with rapidly
progressive invasive cervical cancer is of the utmost importance, as this disease is
almost invariably fatal once it has spread beyond the cervix. Experience at this
institution suggests that this cancer is not responsive to radiation therapy, thus limiting
effective treatment to radical cancer surgery [8].
The preliminary data presented in this population-based series substantiate our
previous impression that rapidly progressive invasive cervical cancer is a disease of
younger women, and, because it is symptomatic, it is identified most often as stage I
cancer [8]. Surprisingly, these data suggest that it is a disease of middle- and
upper-class women, with two-thirds having an annual income greater than $40,000.
With regard to benign gynecologic disorders, more patients with rapidly progressive
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TABLE 3
Histologic Characteristics of Invasive Cervical Cancer Among Rapidly Progressive and
All Other Cervical Cancer Cases
Rapidly Progressive Invasive
Cervical Cancer Cervical Cancer
n-31 n= 166
Tumor Type
Squamous Cell 55 86
Adenocarcinoma 35 11
Adenosquamous 10 3
cervical cancer are reporting ever having had uterine leiomyomata and vaginitis. It
appears that at least some of the diagnoses ofcervical cancer were missed or delayed
because of the negative Pap smears, leading physicians to ascribe abnormal vaginal
bleeding to uterine leiomyomata and vaginal discharge to nonspecific vaginitis instead
ofevaluating the endocervical canal.
Histologic review ofthe cases showed that 35 percent ofrapidly progressive cervical
cancer patients had adenocarcinoma of the endocervix. This histologic type appears
not toexfoliatecells aswell assquamous carcinoma. Cervical adenocarcinomas are less
likely to be identified by Pap smear screening than squamous cell cancers of the
exocervix, and the patient's symptoms are what lead the physician to evaluate the
endocervical canal [10]. Perhaps squamous carcinomas that are found to be rapidly
progressing also initiate in the endocervix and either are inadequately sampled or are
less likely to exfoliate cells that may be identified by routine cytology techniques. Thus
the concept of rapid progression may reflect inadequate or incomplete cytologic
sampling ofthe endocervix rather than true virulence.
Squamous cell carcinomas are believed to arise in the endocervical canal from the
subcolumnar reserve cells, which form a single layer of cuboidal epithelium [11].
These reserve cells proliferate and stratify intosquamous epithelium, the process being
known as squamous metaplasia. The human papilloma virus (HPV) has been
implicated in the genesis of cervical squamous cancer, and recent in situ DNA
hybridization studies suggest that HPV type 18 is the most common subtype found in
adenocarcinomas ofthe cervix [12], whereas the more common squamous carcinomas
are most often associated with HPV type 16.
From a practical standpoint, our preliminary results suggest that many patients may
have had a technically adequate Pap smear, i.e., both squamous and columnar cells are
present, but may not have had sufficient sampling of the endocervix epithelium to
establish the correct diagnosis. Cotton swabs are still routinely used by many
Connecticut physicians to obtain cytologic material from the endocervical canal. A
much better sampling techinque is now available, using the cytobrush, which has been
demonstrated to lower the number of inadequate smears and false-negative cytology
[13-15].
When patient accrual is completed, detailed analysis ofthe final data will be done in
order to identify risk factors and patients' characteristics associated with rapidly
progressive invasive cervical cancer and toverify the preliminary results reported here.
At this time, however, early results indicate that rapidly progressive invasive cervical
cancer is a disease of women who can afford and do utilize private medical care.
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Physicians should routinely employ the cytobrush technique rather than the cotton
swab to obtain endocervical cytology specimens. A negative Pap smear in no way
guarantees that an endocervical carcinoma is absent. One should not be misled into
believing that abnormal vaginal bleeding is due to a uterine leiomyoma or that a
discharge is due to a nonspecific vaginitis because a Pap smear is negative. Liberal use
of endocervix biopsies is mandatory in the presence of unexplained lower abdominal
pain, vaginal discharge, or vaginal bleeding. Early recognition of rapidly progressive
invasive cervical cancer is the only hope a woman has for successful treatment of this
disease.
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